Fenlai Tan, M.D., Ph.D., is the Senior VP and Chief Medical Officer of Betta Pharmaceuticals Co., Ltd. He holds a Ph.D. degree in medical physiology from University of Arkansas for Medical Sciences, and then completed his post-doctoral fellowship at Cleveland Clinic.
Dr. Fenlai Tan has been actively involved in drug development for decades and is especially experienced in clinical study design and implementation for small molecule anti-cancer targeted drugs. He joined Betta Pharmaceuticals in 2007 where he successfully led the phase I, II, III and IV clinical trials of icotinib (an EGFR tyrosine kinase inhibitor) for the treatment of advanced NSCLC harboring EGFR mutation. In 2011, icotinib (Conmana), as the first home-grown anti-cancer targeted drug, was approved by CFDA and launched in China. A comment titled “Icotinib: kick-starting the Chinese anti-cancer drug industry” was published together with the clinical data of the icotinib phase III study (ICOGEN) on the prestigious medical journal, Lancet Oncology. In addition, Dr. Tan oversees the clinical development (phase I-III clinical studies) of many other innovative drugs at Betta in the field of oncology, diabetes, dermatology, ophthalmology, etc. He and his team have conducted more than 30 clinical studies during the past ten years.
Dr. Fenlai Tan is a clinician and a leading biomedical scientist who has authored more than 40 scientific publications and secured more than 20 patents. In 2014, he was awarded as a Distinguished Expert of China Federation of Returned Overseas Chinese. In 2013, he was selected as a member of the national “Recruitment Program of Global Experts”. Dr. Fenlai Tan currently is member of ASCO, AACR, ESMO, IASLC and ADA.